An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects.
The data that support the findings from the ARCTIC clinical trial (Reference 19) are available from the Leeds Clinical Trials Unit but restrictions apply to the availability of these data, which were used following completion of a Data Sharing Agreement between the universities of Leeds and Leiceste...
Published in: | BMC Research Notes |
---|---|
Main Authors: | , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
BioMed Central
2018
|
Subjects: | |
Online Access: | https://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-018-3391-9 http://hdl.handle.net/2381/42178 https://doi.org/10.1186/s13104-018-3391-9 |
id |
ftleicester:oai:lra.le.ac.uk:2381/42178 |
---|---|
record_format |
openpolar |
spelling |
ftleicester:oai:lra.le.ac.uk:2381/42178 2023-05-15T15:03:34+02:00 An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects. Alharthi, Afaf Beck, Daniel Howard, Dena R. Hillmen, Peter Oates, Melanie Pettitt, Andrew Wagner, Simon D. 2018-05-16T14:24:14Z https://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-018-3391-9 http://hdl.handle.net/2381/42178 https://doi.org/10.1186/s13104-018-3391-9 en eng BioMed Central https://www.ncbi.nlm.nih.gov/pubmed/29739419 BMC Research Notes, 2018, 11:280 https://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-018-3391-9 http://hdl.handle.net/2381/42178 doi:10.1186/s13104-018-3391-9 1756-0500 Copyright © the authors, 2018. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. CC-BY Chronic lymphocytic leukaemia Extracellular vesicle miRNA Journal Article 2018 ftleicester https://doi.org/10.1186/s13104-018-3391-9 2019-03-22T20:25:32Z The data that support the findings from the ARCTIC clinical trial (Reference 19) are available from the Leeds Clinical Trials Unit but restrictions apply to the availability of these data, which were used following completion of a Data Sharing Agreement between the universities of Leeds and Leicester and so are not publicly available. All other data generated or analysed during this study are included in this published article. OBJECTIVES: In vitro culture studies have shown that miR-363 is enriched in extracellular vesicles from chronic lymphocytic leukaemia cells. We wondered whether miR-363 was detectable in plasma, which is an essential precondition for further studies to assess its usefulness as a biomarker. Using samples from two clinical trials: one enrolling patients with advanced disease and the other asymptomatic patients with early stage disease, we determined plasma miR-363 levels and secondly investigated the distribution of this miRNA between plasma and particle bound fractions in patients and normal subjects. RESULTS: Advanced disease (n = 95) was associated with higher levels of miR-363 than early stage disease (n = 45) or normal subjects (n = 11) but there was no association with markers of prognosis. The distribution of specific miRNA between particle bound and plasma protein fractions was investigated using size exclusion chromatography on plasma from patients (n = 4) and normal subjects (n = 3). ~ 20% of total miR-16 and miR-363 is particle bound in patients while there was no detectable particle bound material in normal subjects. Our work demonstrates that miR-363 levels are raised in chronic lymphocytic leukaemia patients and raises the possibility that distribution of circulating miRNA between plasma fractions differs in health and disease. PhD studentship from the government of Saudi Arabia to AA. The UK CLL Trials Biobank, University of Liverpool is funded by Bloodwise. ARCTIC clinical trial funded by the NIHR Health Technology Assessment Programme (NIHR HTA Project Number 07/01/38; ISRCTN16544962). Peer-reviewed Publisher Version Article in Journal/Newspaper Arctic University of Leicester: Leicester Research Archive (LRA) Arctic Leicester ENVELOPE(-116.403,-116.403,55.717,55.717) BMC Research Notes 11 1 |
institution |
Open Polar |
collection |
University of Leicester: Leicester Research Archive (LRA) |
op_collection_id |
ftleicester |
language |
English |
topic |
Chronic lymphocytic leukaemia Extracellular vesicle miRNA |
spellingShingle |
Chronic lymphocytic leukaemia Extracellular vesicle miRNA Alharthi, Afaf Beck, Daniel Howard, Dena R. Hillmen, Peter Oates, Melanie Pettitt, Andrew Wagner, Simon D. An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects. |
topic_facet |
Chronic lymphocytic leukaemia Extracellular vesicle miRNA |
description |
The data that support the findings from the ARCTIC clinical trial (Reference 19) are available from the Leeds Clinical Trials Unit but restrictions apply to the availability of these data, which were used following completion of a Data Sharing Agreement between the universities of Leeds and Leicester and so are not publicly available. All other data generated or analysed during this study are included in this published article. OBJECTIVES: In vitro culture studies have shown that miR-363 is enriched in extracellular vesicles from chronic lymphocytic leukaemia cells. We wondered whether miR-363 was detectable in plasma, which is an essential precondition for further studies to assess its usefulness as a biomarker. Using samples from two clinical trials: one enrolling patients with advanced disease and the other asymptomatic patients with early stage disease, we determined plasma miR-363 levels and secondly investigated the distribution of this miRNA between plasma and particle bound fractions in patients and normal subjects. RESULTS: Advanced disease (n = 95) was associated with higher levels of miR-363 than early stage disease (n = 45) or normal subjects (n = 11) but there was no association with markers of prognosis. The distribution of specific miRNA between particle bound and plasma protein fractions was investigated using size exclusion chromatography on plasma from patients (n = 4) and normal subjects (n = 3). ~ 20% of total miR-16 and miR-363 is particle bound in patients while there was no detectable particle bound material in normal subjects. Our work demonstrates that miR-363 levels are raised in chronic lymphocytic leukaemia patients and raises the possibility that distribution of circulating miRNA between plasma fractions differs in health and disease. PhD studentship from the government of Saudi Arabia to AA. The UK CLL Trials Biobank, University of Liverpool is funded by Bloodwise. ARCTIC clinical trial funded by the NIHR Health Technology Assessment Programme (NIHR HTA Project Number 07/01/38; ISRCTN16544962). Peer-reviewed Publisher Version |
format |
Article in Journal/Newspaper |
author |
Alharthi, Afaf Beck, Daniel Howard, Dena R. Hillmen, Peter Oates, Melanie Pettitt, Andrew Wagner, Simon D. |
author_facet |
Alharthi, Afaf Beck, Daniel Howard, Dena R. Hillmen, Peter Oates, Melanie Pettitt, Andrew Wagner, Simon D. |
author_sort |
Alharthi, Afaf |
title |
An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects. |
title_short |
An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects. |
title_full |
An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects. |
title_fullStr |
An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects. |
title_full_unstemmed |
An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects. |
title_sort |
increased fraction of circulating mir-363 and mir-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects. |
publisher |
BioMed Central |
publishDate |
2018 |
url |
https://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-018-3391-9 http://hdl.handle.net/2381/42178 https://doi.org/10.1186/s13104-018-3391-9 |
long_lat |
ENVELOPE(-116.403,-116.403,55.717,55.717) |
geographic |
Arctic Leicester |
geographic_facet |
Arctic Leicester |
genre |
Arctic |
genre_facet |
Arctic |
op_relation |
https://www.ncbi.nlm.nih.gov/pubmed/29739419 BMC Research Notes, 2018, 11:280 https://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-018-3391-9 http://hdl.handle.net/2381/42178 doi:10.1186/s13104-018-3391-9 1756-0500 |
op_rights |
Copyright © the authors, 2018. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
op_rightsnorm |
CC-BY |
op_doi |
https://doi.org/10.1186/s13104-018-3391-9 |
container_title |
BMC Research Notes |
container_volume |
11 |
container_issue |
1 |
_version_ |
1766335432125054976 |